Freezing and transplanting ovarian tissue for young female cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on ovarian tissue cryopreservation as a method to preserve fertility in young female cancer patients who require immediate treatment that may harm their reproductive capabilities. The approach allows for the freezing of ovarian tissue without the need for ovarian stimulation, which can take time that these patients may not have. The study aims to develop this service locally to provide more options for fertility preservation among this vulnerable population. The research will also explore the outcomes of auto-transplantation of the cryopreserved tissue, particularly in patients who are prepubescent.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients aged from 0-35 years old and diagnosed with cancer e.g., leukaemia, myeloproliferative or myelodysplastic diseases, lymphoma, bone tumours, neurological neoplasms and sarcoma, Paediatric bone marrow transplant patients
* Patients with any illness or who will undergo any type of treatment that may cause irreversible damage to their fertility, such as extensive abdominal surgery, high toxicity medication and treatments;
* Patients suffering from hormone-sensitive malignancies who will undergo medical treatment, such as radiotherapy and chemotherapy that is liable to damage their ovaries and deter them from conception in the future.

Exclusion Criteria:

Patients with no anticipated oncologic therapies Patients who are pregnant Children with one ovary Children deemed high risk for perioperative complications Patients unable to provide consent/assent (i.e. significant psychiatric problems/cognitive delay)

\-

Where it's running

• Hong Kong Children's Hospital
  Hong Kong, Hong Kong Recruiting

Study contacts

• Principal investigator: Jacqueline Pui Wah CHUNG, MBBS — Chinese University of Hong Kong
• Study coordinator: Elaine NG, MPhil
• Email: elaineng@cuhk.edu.hk
• Phone: 35052745

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HR20013 for preventing nausea and vomiting in cancer patients receiving chemotherapy

  This real-world study tests whether HR20013 helps prevent nausea and vomiting in adults with cancer who are getting chemotherapy.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT07874308

• Methylscape test in body fluids for multi-cancer detection in Colombia

  A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07741435

• Ready for Safe Cancer Treatment (RESET): A comprehensive perioperative program for surgical patients

  The RESET program tests a structured, multidisciplinary perioperative plan to improve safety and recovery for adults having planned cancer surgery and older adults having planned non cancer-related surgery.

  Recruiting at 2 sites Regional Specialist Hospital in Wroclaw · Wroclaw, Lower Silesian Voivodeship and 1 other locations · NCT07727876

• How environment and biology together predict health, aging, and death

  Researchers are following adults to see how living conditions and biology together relate to aging and life expectancy, by linking personal health data with environmental and social information over time.

  Recruiting Longevity Metrics, Inc. · Boulder, Colorado · NCT07646782

• Metastatic liver cancer patient registry from multiple Chinese centers

  This is a registry that collects real-world data on adults with liver metastases to understand patterns and prognosis and to support future research.

  Recruiting at 2 sites Anhui Provincial Hospital · Bengbu, Anhui and 2 other locations · NCT07602504

• TriAdeno and N-803 vaccine in early prostate cancer on active surveillance

  A vaccine combo called TriAdeno plus the N-803 drug is being tested to see if it can help slow or stop growth in men with early-stage, low- to intermediate-risk prostate cancer who are being watched rather than treated right away.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07574541

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.